Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin
ConclusionsUse of oral semaglutide 14 mg in patients currently receiving sitagliptin 100 mg substantially increases the budget impact for patients with T2DM whose blood glucose level is not controlled with metformin over a 5-year time horizon for US healthcare payers.
Source: PharmacoEconomics - Category: Health Management Source Type: research
More News: Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Fortamet | Health Management | Janumet | Januvia | Metformin | Study